Original reporting and analysis on the stories shaping biotech.
Gilead paid $3.15 billion upfront for Tubulis before anyone outside the company saw the ovarian cancer data. At ASCO 2026, TUB-040 finally showed its cards: a 61% response rate and 11-month progression-free survival that could reshape the ADC landscape.
The inventor of blockbuster CAR-T therapy Carvykti just launched a new company that ditches gene editing entirely. Wondercel Therapeutics debuted early clinical data at ASCO 2026, and the results are equal parts promising and sobering.
Two biotechs raised $556 million in a single day on the Nasdaq, with both deals upsized due to overwhelming demand. Hemab and Seaport's dual IPOs are the strongest signal yet that biotech's long IPO freeze is finally thawing.
Bristol Myers Squibb is betting up to $15.2 billion on 13 preclinical drugs from China's Hengrui Medicine, none of which have been tested in humans. It's one of the largest China-originated pharma deals ever, and it's landing right in the middle of a geopolitical minefield.
AstraZeneca is pushing two drugs toward approval despite Phase 3 failures, betting that subgroup data and supplemental analyses can overcome the biggest hurdle in drug development. The outcome could redefine what "enough evidence" means for the entire industry.
Agios' next-gen pyruvate kinase activator tebapivat just flunked its phase 2b trial in a blood cancer called lower-risk MDS, and the company is scrapping the entire program. The failure exposes a classic biotech trap: assuming a mechanism that works in genetic anemias will translate to cancer.
The FDA just approved a first-of-its-kind antibiotic that doesn't just protect its partner drug from bacterial enzymes; it fights back on its own. In a head-to-head trial against a heavyweight carbapenem, it won by a 20-point margin.
BMS's next-gen myeloma drug mezigdomide just doubled progression-free survival in a phase 3 trial of heavily pretreated patients. The ASCO 2026 data validate CELMoDs as a potent new drug class that could reshape how we treat one of blood cancer's toughest enemies.
Eli Lilly unveiled early clinical data at ASCO 2026 for a next-generation Nectin-4 ADC that targets the same protein as Padcev but carries a completely different weapon. With Padcev anchoring a multi-billion-dollar bladder cancer franchise, the stakes couldn't be higher.
U.S. lawmakers want to add biotech to the COINS Act, which already restricts investment in AI and chips flowing to China. With nearly 40% of major pharma licensing deals involving Chinese biotechs, the move could fundamentally rewire how drugs get developed.
For 40 years, the protein driving pancreatic cancer was called "undruggable." Revolution Medicines just reported phase 3 results that nearly doubled survival in previously treated patients, and the oncology world is paying attention.
Pfizer is paying $650 million upfront (and up to $10.5 billion total) for 12 early-stage cancer drugs from China's Innovent Biologics. It's one of the largest cross-border biopharma deals ever, and it's landing right in the middle of a U.S.-China geopolitical minefield.
A Shanghai biotech just beat chemotherapy in first-line EGFR-mutant lung cancer with an oral pill, crashing into a $6 billion market dominated by AstraZeneca and J&J. The timing couldn't be more politically charged.
ICON plc overstated revenue by less than 2%, but the fallout wiped $5 billion in market cap in a single day. The largest CRO accounting scandal in memory is raising hard questions about trust across the clinical trials industry.
Gilead just killed the lead drug from its $405 million MiroBio acquisition, adding to a growing list of pricey deals that haven't delivered. As the company books $11.5 billion in new deal charges this year, investors are asking an uncomfortable question: is Gilead getting worse at shopping?
Biopharma companies have pledged a jaw-dropping $292 billion to build drug factories in the U.S. since January. But between 100% tariffs, five-year construction timelines, and a severe talent shortage, the gap between promise and production is wider than anyone wants to admit.
Curium Pharma just slid a $7 billion offer across the table to Lantheus Holdings, the company behind prostate cancer imaging blockbuster Pylarify. If the deal goes through, it would create a global radiopharmaceutical powerhouse and mark one of the biggest PE-backed moves into oncology infrastructure ever.
BMS's CELMoD drug mezigdomide just delivered a major Phase 3 win in multiple myeloma, providing the strongest clinical validation yet for the targeted protein degradation drug class. The implications stretch far beyond one company and one cancer.
A new startup thinks the real reason 94% of brain drugs fail isn't bad science; it's bad trial infrastructure. Kordata Dynamics just emerged from stealth with an AI platform built specifically for neural data, and it's starting in the last place you'd expect.
The FDA is piloting one-day factory inspections powered by AI risk analytics, replacing the traditional week-long deep dive for low-risk facilities. With 2,000 firms uninspected since before the pandemic, the agency is betting that algorithms can tell it where to look and where to move on.
The FDA's vaccine advisory committee met to pick the COVID-19 strain for 2026–2027 shots, with a new recombinant variant called XFG emerging as the leading candidate. But the bigger story might be who's still showing up to get vaccinated at all.
A small Korean biotech just dropped MASH liver disease data that looks competitive with Novo Nordisk's blockbuster semaglutide. The catch? Only 35 patients were in the trial, and the competition is about to get fierce.
Join thousands of biotech professionals who start their day with our free, daily briefing.